The FDA has approved esketamine for adult patients with treatment-resistant depression. The treatment has demonstrated improvement in depression symptoms, as well as sustained improvement in symptoms.
After much anticipation, the FDA has given the nod to the first new type of antidepressant in decades. Yesterday, Janssen announced that the FDA had approved esketamine (Spravato), its nasal spray for use in treatment-resistance depression, which is prevalent in approximately 1 in 3 patients with depression.
The approval of esketamine, to be used in conjunction with an oral antidepressant, is a result of positive data coming from both short- and long-term clinical trials in which patients receiving the treatment demonstrated improvement in depression symptoms, as well as sustained improvement in symptoms. The nasal spray works by targeting the N-methyl-D-aspartate receptor, and ionotropic glutamate receptor in the brain.
“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” said Tiffany Farchione, MD, acting director of the Division of Psychiatry Products in the Center for Drug Evaluation and Research at the FDA, in a statement. “Controlled clinical trials that studied the safety and efficacy of the drug, along with careful review through the FDA’s drug approval process including a robust discussion with our external advisory committees, were important to our decision to approve this treatment.”
In 3 short-term studies, patients were randomized to receive either esketamine or a placebo nasal spray with an oral antidepressant. In one of the studies, esketamine resulted in statistically significant improvement in the severity of depression, with some effects prevalent within 2 days. However, the other 2 trials did not meet the pre-specified statistical tests for demonstrating effectiveness. During the long-term trial, patients who were in stable remission or had stable response and continued treatment with esketamine had a significantly longer time to relapse of depressive symptoms.
“Spravato has the potential to change the treatment paradigm and offer new hope to an estimated one-third of people with major depressive disorder who have not responded to existing therapies," said Mathai Mammen, MD, PhD, global health, Janssen Research & Development, in a statement.
Because of the risk of serious adverse events caused by the treatment, as well as the risk for misuse and abuse of the treatment, once esketamine is indicated for a patient, the patient will self-administer the treatment at a certified treatment center under the advisement of a provider. The most commonly reported side effects of the treatment include nausea, vertigo, anxiety, lethargy, and increased blood pressure.
The approval comes weeks after an FDA advisory panel endorsed the treatment, voting 15-2 in favor of the drug.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More